Swedish Orphan Biovitrum AB/Skr SOBI
08:00
10:05
12:15
14:20
16:25
1D1W1MYTD1Y5YMAX
About Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB is a biotechnology company primarily focused on developing and commercializing specialty pharmaceuticals for rare diseases. The company is active in therapeutics for hematology, immunology, and genetic and metabolic disorders. Swedish Orphan Biovitrum was founded in 2001 and is headquartered in Stockholm, Sweden. The company operates globally, reaching markets in Europe, North America, and other regions. A key aspect of its strategic positioning is its commitment to addressing unmet medical needs in rare diseases, which often provides a unique market niche. The company invests significantly in research and development to fuel growth and innovation in its therapeutic areas.
Ticker
Skr SOBI
Sector
Primary listing
XSTO
Employees
1,890
Headquarters
Stockholm, Sweden
Website
SOBI Metrics
BasicAdvanced
kr 117B
9,146.21
kr 0.04
0.17
-
Price and volume
Market cap
kr 117B
Beta
0.17
52-week high
kr 360.60
52-week low
kr 24.78
Average daily volume
449K
Financial strength
Current ratio
1.018
Quick ratio
0.686
Long term debt to equity
25.126
Total debt to equity
37.765
Interest coverage (TTM)
8.01%
Profitability
EBITDA (TTM)
10,577
Gross margin (TTM)
78.16%
Net profit margin (TTM)
0.05%
Operating margin (TTM)
25.62%
Effective tax rate (TTM)
100.71%
Revenue per employee (TTM)
kr 14,740,000
Management effectiveness
Return on assets (TTM)
6.41%
Return on equity (TTM)
0.01%
Valuation
Price to earnings (TTM)
9,146.21
Price to revenue (TTM)
4.195
Price to book
3.26
Price to tangible book (TTM)
-8.52
Price to free cash flow (TTM)
27.791
Free cash flow yield (TTM)
3.60%
Free cash flow per share (TTM)
12.227
Growth
Revenue change (TTM)
9.50%
Earnings per share change (TTM)
-99.63%
3-year revenue growth (CAGR)
16.32%
10-year revenue growth (CAGR)
24.48%
3-year earnings per share growth (CAGR)
-83.56%
10-year earnings per share growth (CAGR)
-16.27%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Swedish Orphan Biovitrum AB stock?
Swedish Orphan Biovitrum AB (SOBI) has a market cap of Skr117B as of January 29, 2026.
What is the P/E ratio for Swedish Orphan Biovitrum AB stock?
The price to earnings (P/E) ratio for Swedish Orphan Biovitrum AB (SOBI) stock is 9146.21 as of January 29, 2026.
Does Swedish Orphan Biovitrum AB stock pay dividends?
No, Swedish Orphan Biovitrum AB (SOBI) stock does not pay dividends to its shareholders as of January 29, 2026.
When is the next Swedish Orphan Biovitrum AB dividend payment date?
Swedish Orphan Biovitrum AB (SOBI) stock does not pay dividends to its shareholders.
What is the beta indicator for Swedish Orphan Biovitrum AB?
Swedish Orphan Biovitrum AB (SOBI) has a beta rating of 0.17. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.